| Literature DB >> 12463469 |
F Huang1, J C C Wei, M Breban.
Abstract
Despite potential side effects dominated by teratogenicity and peripheral neuropathy, thalidomide has recently been used to treat severe ankylosing spondylitis (AS). Over 50 patients have been treated across several 6-12 month open studies. Altogether 68% of the patients improved and the drop-out rate was 19%. Inhibition of NF-kappaB and/or TNFalpha is a putative mechanism for thalidomide efficacy in AS.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12463469
Source DB: PubMed Journal: Clin Exp Rheumatol ISSN： 0392-856X Impact factor: 4.473